You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePimecrolimus
Accession NumberDB00337  (APRD01182)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionPimecrolimus is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream, once marketed by Novartis, (however Galderma will be promoting the molecule in Canada in early 2007) under the trade name Elidel. [Wikipedia]
Structure
Thumb
Synonyms
33-Epi-chloro-33-desoxyascomycin
Pimecrolimus
Pimecrolimusum
External Identifiers
  • ASM 981
  • SDZ ASM 981
  • SDZ ASM-981
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ElidelCream10 mg/gTopicalPhysicians Total Care, Inc.2003-10-30Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
ElidelCream1 %TopicalValeant Canada Lp Valeant Canada S.E.C.2003-03-24Not applicableCanada
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
ElidelCream10 mg/gTopicalValeant Pharmaceuticals North America LLC2001-12-02Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AregenMeda Pharm
RizanEsteve
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7KYV510875
CAS number137071-32-0
WeightAverage: 810.46
Monoisotopic: 809.4480897
Chemical FormulaC43H68ClNO11
InChI KeyKASDHRXLYQOAKZ-XDSKOBMDSA-N
InChI
InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
IUPAC Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0⁴,⁹]octacos-18-ene-2,3,10,16-tetrone
SMILES
[H][C@]1(CC[[email protected]](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([[email protected]](C[[email protected]]2C)OC)[[email protected]](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[[email protected]](O)[[email protected]]1C)OC
Pharmacology
IndicationFor treatment of mild to moderate atopic dermatitis.
Structured Indications
PharmacodynamicsPimecrolimus is a chemical that is used to treat atopic dermatitis (eczema). Atopic dermatitis is a skin condition characterized by redness, itching, scaling and inflammation of the skin. The cause of atopic dermatitis is not known; however, scientists believe that it may be due to activation of the immune system by various environmental or emotional triggers. Scientists do not know exactly how pimecrolimus reduces the manifestations of atopic dermatitis, but pimecrolimus reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system. Pimecrolimus prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Pimecrolimus also reduces the ability of mast cells to release chemicals that promote inflammation.
Mechanism of actionPimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. Also, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/lgE.
TargetKindPharmacological actionActionsOrganismUniProt ID
Serine/threonine-protein kinase mTORProteinyes
potentiator
HumanP42345 details
Peptidyl-prolyl cis-trans isomerase FKBP1AProteinunknown
potentiator
HumanP62942 details
Related Articles
AbsorptionBecause of the low systemic absorption of pimecrolimus following topical application the calculation of standard pharmacokinetic measures such as AUC, Cmax, half-life, etc. cannot be reliably done.
Volume of distributionNot Available
Protein binding74%-87% (in vitro, bound to plasma proteins)
Metabolism

No drug metabolism was observed in human skin in vitro. Oral administration yielded metabolites produced from O-demethylation and oxygenation reactions.

Route of elimination80% of the drug is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include burning sensation, irritation, pruritus, erythema, and skin infections, at the application site.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 2-Methoxyethanol.Experimental
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 5-androstenedione.Experimental, Illicit
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abatacept.Approved
AbciximabPimecrolimus may increase the anticoagulant activities of Abciximab.Approved
abetimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with abetimus.Investigational
ABR-215757The risk or severity of adverse effects can be increased when Pimecrolimus is combined with ABR-215757.Investigational
AcebutololPimecrolimus may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aceclofenac.Approved
AcenocoumarolPimecrolimus may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinPimecrolimus may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pimecrolimus.Approved
Adefovir DipivoxilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adefovir Dipivoxil.Approved, Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Afelimomab.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldosterone.Experimental
AlefaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.Approved, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.Approved, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alendronic acid.Approved
alicaforsenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with alicaforsen.Investigational
AliskirenPimecrolimus may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololPimecrolimus may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pimecrolimus.Approved, Investigational
ALT-110The risk or severity of adverse effects can be increased when Pimecrolimus is combined with ALT-110.Investigational
AltretamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Altretamine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amcinonide.Approved
Amg 827The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amg 827.Investigational
AmikacinPimecrolimus may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePimecrolimus may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinPimecrolimus may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amsacrine.Approved
AnakinraThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.Approved
AncrodPimecrolimus may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anisodamine.Investigational
annamycinPimecrolimus may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
Anti-thymocyte Globulin (Rabbit)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anti-thymocyte Globulin (Rabbit).Approved
AntipyrineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.Approved
Antithrombin III humanPimecrolimus may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Pimecrolimus may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanPimecrolimus may increase the anticoagulant activities of Apixaban.Approved
ApramycinPimecrolimus may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Pimecrolimus can be decreased when combined with Aprepitant.Approved, Investigational
ArbekacinPimecrolimus may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinPimecrolimus may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPimecrolimus may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPimecrolimus may decrease the antihypertensive activities of Arotinolol.Approved
AtazanavirThe metabolism of Pimecrolimus can be decreased when combined with Atazanavir.Approved, Investigational
AtenololPimecrolimus may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azacitidine.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pimecrolimus.Approved
BalsalazidePimecrolimus may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Pimecrolimus.Investigational
BecaplerminPimecrolimus may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPimecrolimus may decrease the antihypertensive activities of Befunolol.Experimental
BelataceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belatacept.Approved
BelimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belimumab.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pimecrolimus.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benoxaprofen.Withdrawn
BenznidazoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole.Investigational
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pimecrolimus.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.Approved, Vet Approved
BetaxololPimecrolimus may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betulinic Acid.Investigational
BevantololPimecrolimus may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Pimecrolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
BisoprololPimecrolimus may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPimecrolimus may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BleomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Blinatumomab.Approved
BoceprevirThe metabolism of Pimecrolimus can be decreased when combined with Boceprevir.Approved
BopindololPimecrolimus may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Pimecrolimus can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pimecrolimus can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brentuximab vedotin.Approved
BriakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Briakinumab.Investigational
BromfenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bucillamine.Investigational
BucindololPimecrolimus may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.Approved
BufuralolPimecrolimus may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanidePimecrolimus may decrease the diuretic activities of Bumetanide.Approved
BupranololPimecrolimus may decrease the antihypertensive activities of Bupranolol.Approved
BusulfanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan.Approved, Investigational
C1 Esterase Inhibitor (Human)The risk or severity of adverse effects can be increased when Pimecrolimus is combined with C1 Esterase Inhibitor (Human).Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Canakinumab.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pimecrolimus.Experimental
CapecitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pimecrolimus.Approved
CarbamazepineThe metabolism of Pimecrolimus can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved
CarmustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPimecrolimus may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPimecrolimus may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Castanospermine.Experimental
CDX-110The risk or severity of adverse effects can be increased when Pimecrolimus is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.Approved, Investigational
CeliprololPimecrolimus may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Pimecrolimus can be increased when it is combined with Ceritinib.Approved
Certolizumab pegolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Certolizumab pegol.Approved
CertoparinPimecrolimus may increase the anticoagulant activities of Certoparin.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorambucil.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pimecrolimus.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pimecrolimus.Approved
CinoxacinPimecrolimus may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinPimecrolimus may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.Approved
Citric AcidPimecrolimus may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
CladribineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pimecrolimus can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clodronate.Approved, Investigational, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine.Approved, Investigational
ClonixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pimecrolimus.Vet Approved
ClotrimazoleThe metabolism of Pimecrolimus can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Pimecrolimus can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Pimecrolimus can be increased when it is combined with Conivaptan.Approved, Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Corticotropin.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Pimecrolimus can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Curcumin.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporinePimecrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with D-Limonene.Investigational
Dabigatran etexilatePimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dacarbazine.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin.Approved
DalteparinPimecrolimus may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPimecrolimus may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarunavirThe metabolism of Pimecrolimus can be decreased when combined with Darunavir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pimecrolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Pimecrolimus can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pimecrolimus.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deoxyspergualin.Investigational
DesirudinPimecrolimus may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pimecrolimus.Approved
DextranPimecrolimus may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pimecrolimus may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pimecrolimus may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pimecrolimus may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pimecrolimus.Approved, Vet Approved
DicoumarolPimecrolimus may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pimecrolimus.Approved
DihydroergotamineThe metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinPimecrolimus may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Pimecrolimus can be decreased when combined with Diltiazem.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dimethyl fumarate.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Pimecrolimus.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pimecrolimus.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxifluridine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pimecrolimus can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Pimecrolimus can be decreased when combined with Dronedarone.Approved
DrospirenonePimecrolimus may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Pimecrolimus is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ebselen.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Eculizumab.Approved, Investigational
Edetic AcidPimecrolimus may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPimecrolimus may increase the anticoagulant activities of Edoxaban.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Pimecrolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pimecrolimus.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pimecrolimus.Approved
EnoxacinPimecrolimus may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinPimecrolimus may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Epirubicin.Approved
EplerenonePimecrolimus may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.Approved
EquileninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilin.Approved
ErythromycinThe metabolism of Pimecrolimus can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Pimecrolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololPimecrolimus may decrease the antihypertensive activities of Esmolol.Approved
EstramustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estramustine.Approved
EstroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone sulfate.Approved
Etacrynic acidPimecrolimus may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.Approved, Investigational
Ethyl biscoumacetatePimecrolimus may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etofenamate.Approved
EtoposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Pimecrolimus can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Everolimus.Approved
exisulindThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Pimecrolimus.Vet Approved
FingolimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fingolimod.Approved, Investigational
FleroxacinPimecrolimus may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pimecrolimus.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with fluasterone.Investigational
FluconazoleThe metabolism of Pimecrolimus can be decreased when combined with Fluconazole.Approved
FludarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.Approved
FluindionePimecrolimus may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePimecrolimus may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorometholone.Approved
FluorouracilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Pimecrolimus.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Pimecrolimus can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pimecrolimus.Approved, Nutraceutical, Vet Approved
FondaparinuxPimecrolimus may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPimecrolimus may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pimecrolimus.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Pimecrolimus can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pimecrolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pimecrolimus.Approved
FosphenytoinThe metabolism of Pimecrolimus can be increased when combined with Fosphenytoin.Approved
FramycetinPimecrolimus may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePimecrolimus may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Pimecrolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with G17DT.Investigational
GabexatePimecrolimus may increase the anticoagulant activities of Gabexate.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gallium nitrate.Approved, Investigational
GarenoxacinPimecrolimus may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPimecrolimus may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemcitabine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pimecrolimus.Approved, Withdrawn
GemifloxacinPimecrolimus may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinPimecrolimus may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPimecrolimus may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APimecrolimus may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Pimecrolimus is combined with GI-5005.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glatiramer Acetate.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glimepiride.Approved
GolimumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Golimumab.Approved
GrepafloxacinPimecrolimus may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GusperimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gusperimus.Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Pimecrolimus is combined with HE3286.Investigational
HeparinPimecrolimus may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Higenamine.Investigational
HirulogPimecrolimus may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Pimecrolimus is combined with HMPL-004.Investigational
HydralazinePimecrolimus may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pimecrolimus.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hydroxyurea.Approved
Hygromycin BPimecrolimus may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icatibant.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Pimecrolimus can be increased when it is combined with Idelalisib.Approved
idraparinuxPimecrolimus may increase the anticoagulant activities of idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ifosfamide.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pimecrolimus.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imiquimod.Approved, Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.Approved
IndenololPimecrolimus may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Pimecrolimus can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pimecrolimus.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indoprofen.Withdrawn
InfliximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Pimecrolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pimecrolimus is combined with INGN 225.Investigational
INNO-206Pimecrolimus may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe metabolism of Pimecrolimus can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Pimecrolimus can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Pimecrolimus can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pimecrolimus can be increased when it is combined with Ivacaftor.Approved
KanamycinPimecrolimus may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Pimecrolimus can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pimecrolimus.Approved
L-PhenylalanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with L-Phenylalanine.Approved, Nutraceutical
LabetalolPimecrolimus may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.Approved
LepirudinPimecrolimus may increase the anticoagulant activities of Lepirudin.Approved
LevobunololPimecrolimus may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPimecrolimus may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Pimecrolimus.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pimecrolimus.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.Approved
LomefloxacinPimecrolimus may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomustineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lomustine.Approved
LopinavirThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.Approved
LovastatinThe metabolism of Pimecrolimus can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
LuliconazoleThe serum concentration of Pimecrolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Pimecrolimus can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Pimecrolimus.Vet Approved
Lx211The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lx211.Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pimecrolimus.Approved
ME-609The risk or severity of adverse effects can be increased when Pimecrolimus is combined with ME-609.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mechlorethamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mercaptopurine.Approved
MesalazinePimecrolimus may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.Withdrawn
MethotrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPimecrolimus may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.Approved
MetoprololPimecrolimus may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePimecrolimus may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Pimecrolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pimecrolimus.Approved
MitomycinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitomycin.Approved
MitotaneThe serum concentration of Pimecrolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Pimecrolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pimecrolimus.Approved
MometasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pimecrolimus.Approved
MoxifloxacinPimecrolimus may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nabumetone.Approved
NadololPimecrolimus may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPimecrolimus may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Pimecrolimus can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naftifine.Approved
Nalidixic AcidPimecrolimus may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Pimecrolimus is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Pimecrolimus is combined with NCX 4016.Investigational
NeaminePimecrolimus may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Pimecrolimus can be decreased when combined with Nelfinavir.Approved
NemonoxacinPimecrolimus may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPimecrolimus may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nepafenac.Approved
NetilmicinPimecrolimus may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Pimecrolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pimecrolimus can be decreased when combined with Nevirapine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Niflumic Acid.Approved
NilotinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nitroaspirin.Investigational
NorfloxacinPimecrolimus may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.Approved
OfloxacinPimecrolimus may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Pimecrolimus can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pimecrolimus.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.Approved
OlsalazinePimecrolimus may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pimecrolimus.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Pimecrolimus can be increased when it is combined with Osimertinib.Approved
OtamixabanPimecrolimus may increase the anticoagulant activities of Otamixaban.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.Approved
OxprenololPimecrolimus may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pamidronate.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Parecoxib.Approved
ParomomycinPimecrolimus may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.Approved
PazufloxacinPimecrolimus may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPimecrolimus may increase the neuroexcitatory activities of Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.Approved, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.Approved, Investigational
PenbutololPimecrolimus may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Pimecrolimus can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentostatinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pentostatin.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pimecrolimus.Approved
PhenindionePimecrolimus may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Pimecrolimus can be increased when combined with Phenobarbital.Approved
PhenprocoumonPimecrolimus may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Pimecrolimus can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPimecrolimus may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirarubicin.Investigational
PiretanidePimecrolimus may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.Approved, Investigational
PlicamycinPimecrolimus may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pimecrolimus.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Pimecrolimus can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPimecrolimus may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pralatrexate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Pimecrolimus can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pimecrolimus can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Procarbazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Propacetamol.Approved
PropranololPimecrolimus may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Pimecrolimus.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Pimecrolimus.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Pimecrolimus.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Pimecrolimus.Vet Approved
Protein CPimecrolimus may increase the anticoagulant activities of Protein C.Approved
Protein S humanPimecrolimus may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePimecrolimus may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPimecrolimus may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Pimecrolimus is combined with PTC299.Investigational
PuromycinPimecrolimus may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pimecrolimus.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pimecrolimus.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Pimecrolimus.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pimecrolimus.Approved
RanolazineThe metabolism of Pimecrolimus can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pimecrolimus.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.Experimental, Investigational
ReviparinPimecrolimus may increase the anticoagulant activities of Reviparin.Approved
RibostamycinPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Pimecrolimus can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pimecrolimus can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pimecrolimus can be increased when combined with Rifapentine.Approved
RilonaceptThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rilonacept.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Pimecrolimus can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.Approved
RivaroxabanPimecrolimus may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pimecrolimus.Approved
RosoxacinPimecrolimus may increase the neuroexcitatory activities of Rosoxacin.Approved
RuxolitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pimecrolimus.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.Experimental
SaquinavirThe metabolism of Pimecrolimus can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pimecrolimus.Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Secukinumab.Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seocalcitol.Experimental
SeratrodastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Pimecrolimus can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pimecrolimus can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pimecrolimus.Approved
SirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sirolimus.Approved, Investigational
SisomicinPimecrolimus may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sorafenib.Approved, Investigational
SotalolPimecrolimus may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPimecrolimus may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPimecrolimus may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinPimecrolimus may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pimecrolimus.Approved
SpironolactonePimecrolimus may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Pimecrolimus is combined with SRT501.Investigational
St. John's WortThe serum concentration of Pimecrolimus can be decreased when it is combined with St. John's Wort.Nutraceutical
SteproninThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Stepronin.Approved
StiripentolThe serum concentration of Pimecrolimus can be increased when it is combined with Stiripentol.Approved
StreptomycinPimecrolimus may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.Approved
SulfasalazinePimecrolimus may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Pimecrolimus can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulindac.Approved
SulodexidePimecrolimus may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Pimecrolimus.Investigational
SunitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tacrolimus.Approved, Investigational
TacrolimusPimecrolimus may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Pimecrolimus.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pimecrolimus.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pimecrolimus.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Pimecrolimus can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Pimecrolimus can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.Approved, Investigational
TemafloxacinPimecrolimus may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pimecrolimus.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teniposide.Approved
TenofovirThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teriflunomide.Approved
TG4010The risk or severity of adverse effects can be increased when Pimecrolimus is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thiotepa.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Pimecrolimus can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tiludronate.Approved, Vet Approved
TimololPimecrolimus may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tioguanine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tixocortol.Approved
TobramycinPimecrolimus may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.Approved
TopotecanThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Topotecan.Approved, Investigational
TorasemidePimecrolimus may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trabectedin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pimecrolimus.Approved
TranilastThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Pimecrolimus.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab emtansine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.Approved, Vet Approved
TriamterenePimecrolimus may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pimecrolimus.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trisalicylate-choline.Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trofosfamide.Investigational
TrovafloxacinPimecrolimus may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pimecrolimus.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ustekinumab.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinPimecrolimus may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pimecrolimus.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vedolizumab.Approved
VenlafaxineThe metabolism of Pimecrolimus can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vindesine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Pimecrolimus can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPimecrolimus may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPimecrolimus may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Pimecrolimus may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.Withdrawn
ZorubicinPimecrolimus may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Viktor Gyollai, Csaba Szabo, “Methods of preparing pimecrolimus.” U.S. Patent US20060142564, issued June 29, 2006.

US20060142564
General References
  1. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264-73. [PubMed:10468798 ]
External Links
ATC CodesD11AH02
AHFS Codes
  • 84:92.00
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6208
Blood Brain Barrier-0.9554
Caco-2 permeable-0.5764
P-glycoprotein substrateSubstrate0.8064
P-glycoprotein inhibitor IInhibitor0.8064
P-glycoprotein inhibitor IIInhibitor0.7014
Renal organic cation transporterNon-inhibitor0.8556
CYP450 2C9 substrateNon-substrate0.9117
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.7519
CYP450 1A2 substrateNon-inhibitor0.8678
CYP450 2C9 inhibitorNon-inhibitor0.8671
CYP450 2D6 inhibitorNon-inhibitor0.9026
CYP450 2C19 inhibitorNon-inhibitor0.8248
CYP450 3A4 inhibitorNon-inhibitor0.8672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9326
Ames testNon AMES toxic0.6495
CarcinogenicityNon-carcinogens0.9183
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.6919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Non-inhibitor0.6886
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
CreamTopical1 %
CreamTopical10 mg/g
Prices
Unit descriptionCostUnit
Elidel 100 Gram Tube 1% 100 gm Tube315.76USD tube
Elidel 60 Gram Tube 1% 60 gm Tube200.05USD tube
Elidel 30 Gram Tube 1% 30 gm Tube101.44USD tube
Elidel 1% cream3.21USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2200966 No2006-12-192015-10-26Canada
US5912238 Yes1996-12-152016-12-15Us
US6352998 Yes1996-04-262016-04-26Us
US6423722 Yes1998-12-262018-12-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP4.36ALOGPS
logP6.81ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area158.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity214.03 m3·mol-1ChemAxon
Polarizability87.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Cyclohexyl halide
  • Oxane
  • Piperidine
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Lactone
  • Secondary alcohol
  • Cyclic ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Azacycle
  • Oxacycle
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Alcohol
  • Alkyl chloride
  • Alkyl halide
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organochloride
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Carbonyl group
  • Organohalogen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
potentiator
General Function:
Type i transforming growth factor beta receptor binding
Specific Function:
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins....
Gene Name:
FKBP1A
Uniprot ID:
P62942
Molecular Weight:
11950.665 Da
References
  1. Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8. [PubMed:12113647 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck JP, Schweitzer A, Berthier S, Moenius T, Grassberger MA: Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74. Epub 2006 Feb 7. [PubMed:16467136 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 04:02